Phaseline

Targets › CD137

CD137 (Tumor necrosis factor receptor superfamily member 9): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 4 Phase 1; Oncology; next expected readout Apr 2027.

Receptor for TNFSF9/4-1BBL. Conveys a signal that enhances CD8(+) T-cell survival, cytotoxicity, and mitochondrial activity, thereby promoting immunity against viruses and tumors (Probable). (UniProt, Q07011)

Open in Phaseline: the race on CD137, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hadassah Medical OrganizationA2/4-1BBL melanoma vaccine
4-1BBL expressing melanoma cell vaccine
CD137Phase 1Malignant MelanomaApr 2027
Zhou ChengzhiKarelizumab
CD137 (4-1BB) agonist antibody
CD137Phase 1Lung CancerAug 2027
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAGEN2373
CD137 (4-1BB) agonist antibody
CD137Phase 1Pancreatic CancerDec 2028
AdageneADG206
activatable anti-CD137 monoclonal antibody (IgG1 co-stimulatory agonist)
CD137Phase 1Advanced/Metastatic Solid Tumors–

Conditions

Lung Cancer (1) Pancreatic Cancer (1) Advanced/Metastatic Solid Tumors (1) Malignant Melanoma (1)

Modalities

mixed (2), antibody (1), small molecule (1)

Companies

Zhou Chengzhi (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) Adagene (1) Hadassah Medical Organization (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.